{"id":"spikevax-omicron-xbb-1-5","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain"},{"rate":"30-50","effect":"Fatigue"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Myalgia"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL5314803","moleculeType":"Oligonucleotide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains lipid nanoparticles encapsulating mRNA encoding the spike protein of the XBB.1.5 Omicron subvariant. Upon intramuscular injection, the mRNA is translated by host cells to produce spike protein antigen, which stimulates both humoral (antibody) and cellular (T-cell) immune responses. This updated formulation targets circulating Omicron subvariants to enhance protection against current variants of concern.","oneSentence":"Spikevax Omicron XBB.1.5 is an mRNA vaccine that instructs cells to produce the spike protein of the XBB.1.5 Omicron variant of SARS-CoV-2, triggering an immune response to protect against COVID-19 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:48.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (booster dose)"}]},"trialDetails":[{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Spikevax Omicron XBB.1.5","genericName":"Spikevax Omicron XBB.1.5","companyName":"Jules Bordet Institute","companyId":"jules-bordet-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Spikevax Omicron XBB.1.5 is an mRNA vaccine that instructs cells to produce the spike protein of the XBB.1.5 Omicron variant of SARS-CoV-2, triggering an immune response to protect against COVID-19 infection. Used for COVID-19 prevention in adults (booster dose).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}